Abstract CT052: Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)Xinxin Wang, Xi Zhang, Zhimin Li et al.|Cancer Research|2020Cited by 30
Long Noncoding RNA SOX2-OT Aggravates Doxorubicin-Induced Apoptosis of Cardiomyocyte by Targeting miR-942-5p/DP5Haining Wang, Xu Tan|Drug Design Development and Therapy|2021Cited by 20
Efficacy and toxicity of <scp>CLAG</scp> combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemiaHan Yao, Xi Zhang, Xu Tan et al.|Cancer Medicine|2023Cited by 10
Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell TransplantationXu Tan, Shifeng Lou, Xiaoqi Wang et al.|Current Medical Science|2023Cited by 8
Abstract LB147: Updates on clinical safety and efficacy result of GC027, the first-in-human, “Off-the-Shelf” CD7 CAR-T stand-alone therapy for adult patients with relapsed/refractory T-cell lymphoblastic leukemia (r/r T-ALL)Shiqi Li, Xi Zhang, Lei Gao et al.|Cancer Research|2021Cited by 4